Context Therapeutics is trading at $0.20, up 5.76%, with no reported company-specific catalyst for its November 2 move. - The gain coincides with a broader market rebound: U.S. futures rose as investors recovered from last week’s tech selloff. - The broader risk-on backdrop may be contributing, but available reporting does not directly attribute the move to it. The latest identified company news was its September 9 CT-202 trial update.